Strontium Ranelate (Fujisawa/Servier)

[en] Strontium ranelate (PROTELOS), a divalent strontium salt, has been developed and launched by Servier for the treatment of osteoporosis. Fujisawa Pharmaceutical is developing the drug in Japan; in November 2004, phase II Japanese trials were ongoing.

Disciplines :

Rheumatology
Public health, health care sciences & services

Author, co-author :

Jupsin, Isabelle ; Centre Hospitalier Universitaire de Liège - CHU > Médecine de l'appareil locomoteur

Collette, Julien ; Centre Hospitalier Universitaire de Liège - CHU > Chimie médicale

Henrotin, Yves ; Université de Liège - ULiège > Unité de recherche sur l'os et le cartillage (U.R.O.C.)

Bruyère, Olivier ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique

Sarlet, Nathalie ; Centre Hospitalier Universitaire de Liège - CHU > Médecine de l'appareil locomoteur

Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique

Language :

English

Title :

Strontium Ranelate (Fujisawa/Servier)

Publication date :

April 2005

Journal title :

Current Opinion in Investigational Drugs

ISSN :

1472-4472

Publisher :

Current Drugs, United Kingdom

Volume :

Issue :

Pages :

435-44

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 15 March 2011

Statistics

Number of views

115 (8 by ULiège)

Number of downloads

2 (2 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

Bibliography

52280 An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats. Marie P, Hott M, Modrowski D, De Pollak C, Guillemain J, Deloffre P, Tsouderos Y J BONE MINER RES 1993 8 5 607-615
287535 Treatment of postmenopausal osteoporosis. Eastell R N ENGL J MED 1998 338 11 736-746
344627 The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro. Canalis E, Hott M, Deloffre P, Tsouderos Y, Marie PJ BONE 1996 18 6 517-523
352094 Endothelin and endothelin receptor antagonists in cardiovascular disease. Ruschitzka F, Noll G, Shaw S, Luscher TF J HYPERTENS SUPPL 1998 16 8 S13-S23
411810 Fujisawa squires an agent to treat osteoporosis from Servier. Fujisawa Pharmaceutical Co Ltd PRESS RELEASE 2001 May 18
466438 In vitro effects of S12911-2 on osteoclast function and bone marrow macrophage differentiation. Baron R, Tsouderos Y EUR J PHARMACOL 2002 450 1 11-17
498227 S 12911-2 inhibits osteoclastic bone resorption in vitro. Takahashi N, Sasaki T, Tsouderos Y, Suda T J BONE MINER RES 2003 18 6 1082-1087
498231 Design and methodology of the phase 3 trials for the clinical development of strontium ranelate in the treatment of women with postmenopausal osteoporosis. Meunier PJ, Reginster JY OSTEOPOROSIS INT 2003 14 3 S66-S76
498232 Strontium ranelate phase 2 dose-ranging studies: PREVOS and STRATOS studies. Reginster JY, Meunier PJ OSTEOPOROSIS INT 2003 14 3 S56-S65
498242 Strontium ranelate: Dose-dependent effects in established postmenopausal vertebral osteoporosis - a 2-year randomized placebo controlled trial. Meunier PJ, Slosman DO, Delmas PD, Sebert JL, Brandi ML, Albanese C, Lorenc R, Nielsens P, De Vernejoul MC, Roces A, Reginster JY J CLIN ENDOCRINOL METAB 2002 87 5 2060-2066
498244 Prevention of early postmenopausal bone loss by strontium ranelate: The randomized, two-year, double-masked, dose-ranging, placebo-controlled PREVOS trial. Reginster JY, Deroisy R, Dougados M, Jupsin I, Colette J, Roux C OSTEOPOROSIS INT 2002 13 12 925-931
498245 Long-term treatment with strontium ranelate increases vertebral bone mass without deleterious effect in mice. Delannoy P, Bazot D, Marie PJ METAB CLIN EXP 2002 51 7 906-911
498256 Incorporation and distribution of strontium in bone. Dahl SG, Allain P, Marie PJ, Mauras Y, Boivin G, Ammann P, Tsouderos Y, Delmas PD, Christiansen C BONE 2001 28 4 446-453
498272 Strontium ranelate increases cartilage matrix formation. Henrotin Y, Labasse A, Zheng SX, Galais P, Tsouderos Y, Crielaard JM, Reginster JY J BONE MINER RES 2001 16 2 299-308
498274 Long-term strontium ranelate administration in monkeys: Effects on mineral crystals and on the degree of mineralization of bone. Boivin GY, Farlay D, Panczer G, Dupin-Roger I, Simi C, Buffet A, Tupinon-Mathieu I, Meunier PJ J BONE MINER RES 2001 16 1 Abs S293
498276 Strontium ranelate inhibits bone resorption while maintaining bone formation in alveolar bone in monkeys (Macaca fascicularis). Buehler J, Chappuis P, Saffar JL, Tsouderos Y, Vignery A BONE 2001 29 2 176-179
498278 Strontium deposition in bone is dose dependent and does not alter the degree of mineralization of bone in osteoporotic patients treated with strontium ranelate. Boivin GY, Foos E, Tupinon-Mathieu I, Meunier PJ J BONE MINER RES 2000 15 1 Abs S305
498281 Uptake and distribution of strontium in human bone, evolution of the degree of mineralisation after strontium ranelate administration. Boivin G, Schenker E, Tupinon-Mathieu I, Meunier PJ J BONE MINER RES 1999 14 1 Abs S284
498284 Strontium distribution and interactions with bone mineral in monkey iliac bone after strontium salt (S 12911) administration. Boivin G, Deloffre P, Perrat B, Panczer G, Boudeulle M, Mauras Y, Allain P, Tsouderos Y, Meunier PJ J BONE MINER RES 1996 11 9 1302-1311
512418 Fujisawa announces interim financial results for FY 03/2004 and revises its full year forecasts. Fujisawa Pharmaceutical Co Ltd PRESS RELEASE 2003 October 30
518146 We wish to become a global player after 2005: Dr Aoki of Fujisawa. PHARMA JPN 2003 December 08 1-3
525100 Products under clinical development. Fujisawa Pharmaceutical Co Ltd PRESS RELEASE 2004 February 25
550757 Effects of strontium on calcium metabolism in rats. II. Strontium prevents the increased rate of bone turnover in ovariectomized rats. Morohashi T, Sano T, Harai K, Yamada S JPN J PHARMACOL 1995 68 2 153-159
550759 S12911-2 reduces bone loss induced by short-term immobilization in rats. Hott M, Deloffre P, Tsouderos Y, Marie PJ BONE 2003 33 1 115-123
550767 The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R et al N ENGL J MED 2004 350 5 459-468
551750 Company website. Servier COMPANY WORLD WIDE WEB SITE 2004 July 30
553123 Fujisawa announce financial results for 1st quarter of FY 03/2005. Fujisawa Pharmaceutical Co Ltd PRESS RELEASE 2004 July 30
561005 PROTELOS, the new antiosteoporotic treatment developed by Servier, has just received its approval in the European Union. Servier PRESS RELEASE 2004 September 22
569053 Fujisawa announces interim financial results for FY 03/2005 and revises its full year forecasts. Fujisawa Pharmaceutical Co Ltd PRESS RELEASE 2004 November 04
572065 American College of Rheumatology - 68th Annual Scientific Meeting, San Antonio, TX, USA. Sylvester B IDDB MEETING REPORT 2004 October 16-21
576183 Pharmacologic prevention of osteoporotic fractures. Zizic TM AM FAM PHYS 2004 70 7 1293-1300
577449 New this month: PROTELOS. MIMS (LONDON) 2004 December 01 5
578974 In vitro effects of strontium ranelate on the extracellular calcium-sensing receptor. Coulombe J, Faure H, Robin B, Ruat M BIOCHEM BIOPHYS RES COMMUN 2004 323 4 1184-1190
578976 Strontium ranelate improves bone resistance by increasing bone mass and improving architecture in intact female rats. Ammann P, Shen V, Robin B, Mauras Y, Bonjour JP, Rizzoli R J BONE MINER RES 2004 12 2012-2020
579076 Osteoporosis: A review. Lin JT, Lane JM CLIN ORTHOP RELAT RES 2004 425 126-134
579154 Normal matrix mineralization induced by strontium ranelate in MC3T3-E1 osteogenic cells. Barbara A, Delannoy P, Denis BG, Marie PJ METABOLISM 2004 53 4 532-537
579414 The biological role of strontium. Nielson SP BONE 2004 35 3 583-588
579932 The usefulness of strontium as an adjuvant to calcium in the remineralization of the skeleton in man. Shorr E BULLETIN: HOSPITAL JOINT DIS 1952 13 1 59-66
580404 Strontium ranelate in osteoporosis. Reginster JY CURR PHARM DESIGN 2002 8 21 1907-1916
581705 Healthcare professionals - osteoporosis: PROTELOS - European summary of product characteristics. Servier COMPANY WORLD WIDE WEB SITE 2005 January 26
581706 Mechanisms of action and therapeutic potential of strontium in bone. Marie PJ, Ammann P, Boivin G, Rey C CALCIF TISSUE INT 2001 69 3 121-129
581707 Effect of low doses of stable strontium on bone metabolism in rats. Marie PJ, Garba MT, Hott M, Miravet L MINER ELECTROLYTE METABOL 1985 11 1 5-13
581709 Short-term effects of fluoride and strontium on bone formation and resorption in the mouse. Marie PJ, Hott M METAB CLIN EXP 1986 35 6 541-551
581710 Effects of low doses of strontium on bone quality and quantity in rats. Grynpas MD, Marie PJ BONE 1990 11 5 313-319
581711 Strontium increases vertebral bone volume in rats at a low dose that does not induce detectable mineralization defect. Grynpas MD, Hamilton E, Cheung R, Tsouderos Y, Deloffre P, Hott M, Marie PJ BONE 1986 18 3 253-259
585876 Drug development pipeline. Sakai F, Takeuchi K DEUTSCHE BANK SECURITIES LTD 2004 December 06
585879 Yamanouchi Pharmaceutical. Ohmi M, Buchner D, Tomisawa A JP MORGAN 2004 November 16